Effectiveness of Golimumab in Clinical Management of Patients with Rheumatoid Arthritis
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effectiveness of Golimumab in Clinical Management of Patients with Rheumatoid Arthritis
Authors
Keywords
Rheumatoid Arthritis, Infliximab, Adalimumab, Biological Agent, Golimumab
Journal
Drugs in research & development
Volume 13, Issue 1, Pages 95-100
Publisher
Springer Nature
Online
2013-04-03
DOI
10.1007/s40268-013-0010-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biologic Agents in Rheumatoid Arthritis: An Update for Managed Care Professionals
- (2016) Sandeep K. Agarwal JOURNAL OF MANAGED CARE PHARMACY
- Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
- (2014) K Malottki et al. HEALTH TECHNOLOGY ASSESSMENT
- Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α
- (2014) David J. Shealy et al. mAbs
- Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks
- (2012) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
- (2012) Jasvinder A. Singh et al. ARTHRITIS CARE & RESEARCH
- Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
- (2011) Yoshiya Tanaka et al. ANNALS OF THE RHEUMATIC DISEASES
- Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years
- (2011) M. U. Rahman et al. ANNALS OF THE RHEUMATIC DISEASES
- The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy
- (2011) Paul Emery et al. ARTHRITIS AND RHEUMATISM
- Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database
- (2011) Yohei Seto et al. Modern Rheumatology
- Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study
- (2010) E. Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
- (2010) J. S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
- (2010) Daniel Aletaha et al. ARTHRITIS AND RHEUMATISM
- Golimumab as the first monthly subcutaneous fully human anti-TNF-α antibody in the treatment of inflammatory arthropathies
- (2010) Gabor Hutas Immunotherapy
- Golimumab and malignancies: true or false association?
- (2010) Ines Zidi et al. MEDICAL ONCOLOGY
- Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register
- (2010) W. Kievit et al. RHEUMATOLOGY
- Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis
- (2009) Paul Emery et al. ARTHRITIS AND RHEUMATISM
- Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
- (2009) Josef S Smolen et al. LANCET
- Golimumab, a human antibody to tumour necrosis factor given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
- (2008) E C Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started